Pyridopyrimidinone inhibitors of viruses

Patent metadata

Field	Value
Publication number	US-9567331-B2
Application number	US-201214357920-A
Country	US
Kind code	B2
Filing date	Nov 15, 2012
Priority date	Nov 15, 2011
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Provided herein are novel small molecule pyridomyrimidone viral inhibitor agents of Formula (I), such as 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[1,2-f]pyrimidin-1-one, and methods of using pharmaceutical or therapeutic compositions comprising such viral inhibitor agents of Formula (I) in inhibiting and treating viral infections including orthopox and retroviral infections. Methods of synthesizing such agents are also provided herein.

First claim

We claim:

1. A pharmaceutical composition comprising a pyridopyrimidinone viral inhibitor of chemical structure:

2. A method of treating an orthopoxvirus infection in a subject in need thereof, the method comprising administering to a subject having an orthopoxvirus infection, a therapeutically effective amount of any of the pharmaceutical compositions of claim 1 .

3. The method of claim 2 , wherein the orthopoxvirus is a Vaccinia virus or a Variola virus.

4. The method of claim 2 , further comprising administration of one or more additional orthopoxvirus therapeutic agents.

5. A method of treating a lentivirus infection in a subject in need thereof, the method comprising administering to a subject having a lentivirus infection a therapeutically effective amount of any of the pharmaceutical compositions of claim 1 .

6. The method of claim 5 , wherein the lentivirus is HIV.

7. The method of claim 5 , further comprising administration of one or more additional retroviral therapeutic agents.

8. The method of claim 7 , wherein the retroviral therapeutic agent is an anti-HIV agent.

9. A method of inhibiting viral replication comprising contacting a cell infected with a virus with an effective amount of a pharmaceutical composition claim 1 , wherein the virus is an orthopoxvirus or a lentivirus.

10. The method of claim 9 , wherein the contacting is in vitro or ex vivo.

11. The method of claim 9 , wherein the contacting is in vivo.

12. The method of claim 9 , wherein the virus is an orthopoxvirus.

13. The method of claim 9 , wherein the retrovirus is a lentivirus.

14. The method of claim 13 , wherein the lentivirus is HIV.

15. The pharmaceutical composition of claim 1 , wherein the pyridopyrimidinone viral inhibitor of Formula (I) is 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[1,2-f]pyrimidin-1-one (CMLDBU6128), having a chemical structure:

Assignees

• Univ Boston

Inventors

• Schaus Scott E
• Brown Lauren
• Connor John
• Dower Ken William

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12Q1/70

  involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)} · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title